secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2026-08-05T11:05:06+00:00
Accession:  0001193125-26-333820
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q2 net income $4.6M on $25M Nestlé milestone; cash runway through Q1 2027
-------------------------------------------------------------------------------

- Net income of $4.6M vs net loss of $19.9M YoY; $25M gain from Nestlé milestone termination payment.
- Cash and equivalents $15.6M at June 30; expects additional $12.5M from Nestlé in Oct 2026; funds operations through Q1 2027.
- SER-155 in irEC: 80% (12/15) achieved immunosuppressive-free clinical response at day 15 in MSK IST.
- Terminated 200 Sidney Street lease; further reduces annual facility cash costs from 2027.
- Engaging partners for SER-155 (allo-HCT, irEC) and SER-603 (IBD); seeking capital to advance pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/0001193125-26-333820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/d124829d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-333820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer